Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person23
Liminatus Pharma, Inc.
Company
Helus Pharma Inc.
Company
IGC Pharma, Inc.
Company
Lantern Pharma Inc.
Company
aTYR PHARMA INC
Company
Silo Pharma, Inc.
Company
Traws Pharma, Inc.
Company
Avalyn Pharma Inc.
Company
Nuvectis Pharma, Inc.
Company
Pharma-Bio Serv, Inc.
Company
SpyGlass Pharma, Inc.
Company
Cocrystal Pharma, Inc.
Company
REGENEREX PHARMA, INC.
Company
BridgeBio Pharma, Inc.
Company
BetterLife Pharma Inc.
Company
LIGAND PHARMACEUTICALS INC
Company
LB PHARMACEUTICALS INC
Company
Propanc Biopharma, Inc.
Company
Nasus Pharma Ltd
Company
GT Biopharma, Inc.
Company
Olema Pharmaceuticals, Inc.
Company
Lyell Immunopharma, Inc.
Company
Cue Biopharma, Inc.
Company
Primary record3
Liminatus Pharma, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On November 2, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with a non-U.S. investor, pursuant to
Liminatus Pharma, Inc. filed 8-K
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on January 15, 2026 Liminatus Pharma, Inc. (the Company ) received a notice from the
Liminatus Pharma, Inc. filed 8-K
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on November 19, 2025, Liminatus Pharma, Inc., a Delaware corporation (the Company ),